Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: Long-term follow-up of the HUNT 1 study

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 614-620

  Vengen, Inga Thorsen ^a   Dale, Ane Cecilie ^a,b   Wiseth, Rune ^a,b   Midthjell, Kristian ^a   Videm, Vibeke ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

HUNT; Inflammation; Ischemic heart disease; Lactoferrin; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; GLUCOSE; LACTOFERRIN; MYELOPEROXIDASE; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LACTOFERRIN; MALE; MYOCARDIAL ISCHEMIA; NEUTROPHILS; PEROXIDASE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS;

EID: 77957698530     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.008     Document Type: Article

References (35)

1. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
2. Lyon C.J., Law R.E., Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195-2200.
3. Levinson S.S. Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test. Clin Chim Acta 2005, 356:1-8.
4. Madjid M., Awan I., Willerson J.T., et al. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004, 44:1945-1956.
5. Angeli F., Angeli E., Ambrosio G., et al. Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk. Obstet Gynecol 2010, 115:695-703.
6. Gach O., Nys M., Deby-Dupont G., et al. Acute neutrophil activation in direct stenting: comparison of stable and unstable angina patients. Int J Cardiol 2006, 112:59-65.
7. Kajikawa M., Ohta T., Takase M., et al. Lactoferrin inhibits cholesterol accumulation in macrophages mediated by acetylated or oxidized low-density lipoproteins. BBA: Lipid Lipid Metab 1994, 1213:82-90.
8. Baveye S., Elass E., Fernig D.G., et al. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 2000, 68:6519-6525.
9. Shurtz-Swirski R., Sela S., Herskovits A.T., et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001, 24:104-110.
10. Holmen J., Midthjell K., Bjartveit K., et al. The North-Trøndelag health survey 1984-86. Purpose, background and methods. Participation, non-participation and frequency distribution 1990, Report no. 4, Statens Institutt for Folkehelse, Senter for Samfunnsmedisinsk Forskning, Oslo, Norway.
11. Dale A.C., Nilsen T.I., Vatten L., et al. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74,914 individuals in the HUNT 1 Study. Eur Heart J 2007, 28:2924-2929.
12. Vengen I.T., Dale A.C., Wiseth R., et al. Neopterin predicts the risk for fatal ischemic heart disease in type 2 diabetes mellitus: long-term follow-up of the HUNT 1 study. Atherosclerosis 2009, 207:239-244.
13. Videm V. Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release. Scand J Immunol 1996, 43:385-390.
14. Hegnhøj J., Schaffalitzky de Muckadell O.B. An enzyme linked immunosorbent assay for measurements of lactoferrin in duodenal aspirates and other biological fluids. Scand J Clin Lab Invest 1985, 45:489-495.
15. Harrell FE. Design version 2.1-1. http://biostatmcvanderbiltedu/S/Design.
16. R Development Core Team R: A language and environment for statistical computing 2010, R Foundation for Statistical Computing, Vienna, Austria. http://wwwr-projectorg/.
17. Norata G.D., Marchesi P., Pulakazhi Venu V.K., et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
18. Alba-Loureiro T.C., Munhoz C.D., Martins J.O., et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007, 40:1037-1044.
19. Tennenberg S.D., Finkenauer R., Dwivedi A. Absence of lipopolysaccharide-induced inhibition of neutrophil apoptosis in patients with diabetes. Arch Surg 1999, 134:1229-1233.
20. Kockx M.M., De Meyer G.R., Jacob W.A., et al. Triphasic sequence of neointimal formation in the cuffed carotid artery of the rabbit. Arterioscler Thromb 1992, 12:1447-1457.
21. Katsura M., Forster L.A., Ferns G.A., et al. Oxidative modification of low-density lipoprotein by human polymorphonuclear leucocytes to a form recognised by the lipoprotein scavenger pathway. Biochim Biophys Acta 1994, 1213:231-237.
22. Videm V., Wiseth R., Gunnes S., et al. Multiple inflammatory markers in patients with significant coronary artery disease. Int J Cardiol 2007, 118:81-87.
23. Collison K.S., Parhar R.S., Saleh S.S., et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002, 71:433-444.
24. Alexiewicz J.M., Kumar D., Smogorzewski M., et al. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med 1995, 123:919-924.
25. Wong R.K.M., Pettit A.I., Davies J.E., et al. Augmentation of the neutrophil respiratory burst through the action of advanced glycation end products: a potential contributor to vascular oxidant stress. Diabetes 2002, 51:2846-2853.
26. Avanzas P., Arroyo-Espliguero R., Cosín-Sales J., et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis 2004, 175:151-157.
27. Crouch S.P., Slater K.J., Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992, 80:235-240.
28. Legrand D., Elass E., Carpentier M., et al. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 2005, 62:2549-2559.
29. Li Y.M. Glycation ligand binding motif in lactoferrin. Implications in diabetic infection. Adv Exp Med Biol 1998, 443:57-63.
30. Sorimachi K., Akimoto K., Hattori Y., et al. Activation of macrophages by lactoferrin: secretion of TNF-alpha, IL-8 and NO. Biochem Mol Biol Int 1997, 43:79-87.
31. Latini R., Maggioni A.P., Peri G., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
32. Loria V., Dato I., Graziani F., et al. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediat Inflamm 2008, 2008:135625.
33. Vita J.A., Brennan M.-L., Gokce N., et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004, 110:1134-1139.
34. Brennan M.-L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
35. Xu X., Håkansson L. Degranulation of primary and secondary granules in adherent human neutrophils. Scand J Immunol 2002, 55:178-188.